Spatial Multiomics Powers Pathology Prediction

Spatial multiomics, still in its discovery phase, can mean different things to different people. It typically denotes the visualization of transcriptomic and proteomic data in the context of tissue architecture, either directly on the same section or on serial sections that are integrated computationally. Spatial multiomics may eventually grow to encompass lipids, glycans, metabolites, epigenetic […]

Nucleai Launches New Multiplex Imaging Spatial Analysis Solution to Increase Reliability and Speed of Immunofluorescence Analysis for Drug Discovery and Development

Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development. Nucleai will present new […]

Nucleai Hopes to Engage Pharma on Next-Gen Immunotherapies With Proof-of-Concept AI-Based Biomarker

NEW YORK –Nucleai researchers investigated whether, by using spatial biology to analyze interactions between the immune system and tumor microenvironment, it is possible to find biomarkers predictive of sensitivity to immuno-oncology drugs. In a retrospective multi-center study conducted in the US and Israel, where the firm is based, Nucleai analyzed biopsy slides and clinical outcomes […]

Israel: An Untapped Biotech Investment Opportunity

With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem on the heels of a renowned high-tech industry. Much more than just the iconic Teva Pharmaceuticals, venture capitalists would do well to pay attention to the innovation stemming from this largely unmined investment opportunity. “Everything about it is about innovation,” said Michael […]

Nucleai, Propath Partnership Paves Way for Spatial Oncology Biomarkers

Spatial biology specialists Nucleai and Propath UK have announced a partnership to develop and validate an immunofluorescence assay focused on 30 immuno-oncology protein targets that could inform the development of novel oncology biomarkers and companion diagnostics. Dr Ken Bloom, head of Pathology at Nucleai, explained that spatial biology—the study of tissues within their multidimensional context—“is considered a new frontier and […]

Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel

Propath UK, Europe’s leading CRO for spatial biology, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking spatial biology insights from pathology data, announce their collaboration to develop and validate a 30-plex immunofluorescence (IF) panel focused on protein targets relevant to immuno-oncology. For our pharmaceutical and biotechnology partners, this groundbreaking panel, in […]

Lunaphore and Nucleai announce a partnership to provide AI-powered spatial biology analysis to accelerate drug development

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. […]

Nucleai Announces New Data Showing Better Prediction of Response to Immune Checkpoint Inhibitors for NSCLC Patients

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced new data showing that the deep learning capabilities of the Nucleai platform accurately analyzed and classified the spatial arrangement of immune cells in the tumor microenvironment (TME) to identify metastatic non-small cell lung cancer (mNSCLC) patients […]

Add Your Heading Text Here